Arthur M. Krieg, M.D. has worked in the field of nucleotide therapeutics since the 1980s. In 2004 he co-founded The Oligonucleotide Therapeutics Society, a non-profit group of scientists dedicated to the development of drugs based on RNA and DNA technologies.
Prior to that he trained in Immunology/Rheumatology at NIH and then joined the University of Iowa, becoming Professor of Internal Medicine. Dr. Krieg discovered the immune stimulatory CpG DNA in 1994, which led to a new approach to vaccine development via immunotherapy and vaccine adjuvants.
Most recently he founded Checkmate Pharmaceuticals in 2015 to develop immune activating CpG for cancer immunotherapy. He is currently Professor in the RNA Therapeutics Institute at the University of Massachusetts.